YOLFTbeta
Puma Biotechnology Inc

Puma Biotechnology Inc

PBYI · NASDAQ · Healthcare / Biotechnology

7.77USD-0.31 (-3.84%)

Price History

Full chart

Market Stats

Previous Close8.08
Open8.08
Day Range7.75 – 8.12
52-Week Range4.58 – 9.98
Volume403.67K
Market Cap506.91M
P/E (TTM)19.25
Forward P/E3.46
EPS0.51
Dividend Yield0.00%
Beta1.23
50-Day Avg8.91
200-Day Avg7.39

About

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Alan H. Auerbach
  • Employees179
  • Headquarters10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024, USA
  • Websitehttps://www.pumabiotechnology.com

Leadership

  • Mr. Alan H. AuerbachFounder, Chairman, President, CEO & Secretary · b. 1970
  • Mr. Maximo F. NouguesCFO & Principal Accounting Officer · b. 1969
  • Mr. Douglas Hunt B.Sc., FRAPSChief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer · b. 1965
  • Mr. Gordon G. EsplinChief Accounting Officer · b. 1968
  • Mr. Mariann OhanesianSenior Director of Investor Relations
  • Ms. Heather BlaberSenior Vice President of Marketing
  • Mr. Roger L. StormsSenior Vice President of Sales
  • Ms. Pamela Wilson BASenior Vice President of Clinical Operations
  • Dr. Petra RietschelSenior Vice President of Clinical Development
  • Mr. Kenneth WieheSenior Vice President of Supply Chain & Manufacturing

Financials

Income Statement

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-----281.10K0000027.70M251.00M272.26M225.11M253.16M228.03M235.64M230.47M228.37M
Growth (%)-----+100.00%-----+806.14%+8.47%-17.32%+12.46%-9.92%+3.34%-2.19%-0.91%
Cost of Revenue----0000776.00K1.15M5.60M34.60M36.81M39.37M63.70M55.09M62.68M64.40M58.16M
Gross Profit-----281.10K000-776.00K-1.15M22.10M216.40M235.44M185.74M189.45M172.94M172.96M166.06M170.21M
Gross Margin----100.00%-----79.78%86.22%86.48%82.51%74.84%75.84%73.40%72.06%74.53%
Operating Expense----9.88M74.40M54.83M142.30M239.52M275.45M314.50M311.10M311.04M216.14M188.16M149.22M140.31M135.10M132.91M
Operating Income-15.09M-14.08K-16.84K-15.98K-10.16M-74.40M-54.83M-142.30M-240.30M-276.60M-292.40M-94.70M-75.59M-30.40M1.29M23.72M32.64M30.97M37.30M
Operating Margin----3613.24%------1055.60%-37.73%-27.77%-13.51%0.51%10.40%13.85%13.44%16.33%
EBITDA-15.09M-14.08K-16.84K-15.98K-10.22M-74.14M-54.41M-141.67M-239.52M-275.45M-288.42M-95.21M-52.45M-35.71M-4.69M21.89M47.52M48.08M53.34M
EBITDA Margin----3636.54%------1041.24%-37.93%-19.26%-15.86%-1.85%9.60%20.17%20.86%23.36%
Net Income-15.09M-14.08K-16.84K-15.98K-10.23M-74.30M-54.66M-142.00M-239.30M-276.00M-292.00M-113.60M-75.59M-59.99M-29.13M2.00K21.59M30.28M31.11M
Net Income Margin----3640.35%------1054.15%-45.26%-27.77%-26.65%-11.51%0.00%9.16%13.14%13.62%
R&D----826.37K49.60M45.05M122.90M208.50M222.80M207.80M164.90M132.85M97.65M71.87M52.24M50.38M54.94M62.07M
R&D as % of Total Revenue-----293.98%-----750.18%65.70%48.80%43.38%28.39%22.91%21.38%23.84%27.18%
Interest Expense00003.78K98.00K172.00K324.00K971.00K958.00K720.00K11.00M15.00M14.05M12.81M11.59M13.33M12.45M6.62M
Interest Expense % of Total Revenue-----1.35%-----2.60%4.38%5.51%6.24%5.06%5.08%5.66%5.40%2.90%

Balance Sheet

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.41M732.41K46255.40M151.70M104.37M162.76M239.84M252.79M165.53M259.12M234.91M244.22M226.59M222.06M230.53M213.33M216.30M
Total Liabilities1.41M2.25K2.27K-1.03M22.79M20.39M45.71M33.84M42.97M112.22M224.82M217.44M250.17M229.03M200.45M177.09M121.21M85.96M
Total Equity1.41M-2.18K13846254.37M128.90M83.99M117.00M206.00M209.80M53.30M34.31M17.46M-5.95M-2.45M21.61M53.44M92.13M130.34M
Cash1.41M732.41K46253.38M137.40M43.04M38.50M31.60M194.50M81.70M108.40M60.04M85.29M63.13M76.20M84.58M69.22M29.64M
Total Debt----------48.48M151.89M120.23M120.95M116.64M114.28M111.49M74.08M28.55M
Net Debt-1.41M-73-2.41K-462-53.38M-137.40M-43.04M-38.50M-31.60M-194.50M-33.22M43.49M60.19M35.66M53.51M38.08M26.91M4.86M-1.09M

Cash Flow

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-15.09M-11.83M-16.82M-18.25M-1.83M-44.00M-55.05M-77.20M-154.50M-141.70M-172.50M-24.10M22.38M800.00K20.65M-15.83M27.01M38.92M41.80M
Investing Cash Flow-----1.75M-1.20M-41.53M-63.30M-85.90M142.20M-15.40M-57.60M5.16M23.30M-10.88M7.10M-19.13M-20.44M-36.19M
Financing Cash Flow16.50M10.50M19.15M16.30M56.95M129.30M2.21M136.00M233.36M162.40M75.10M108.40M-67.07M100.00K-31.93M12.22M2.43M-33.85M-45.20M
Capital Expenditure0000692.75K1.06M628.00K1.29M1.18M7.28M50.43M609.00K306.00K20.05M1.00K7.00M12.64M56.00K71.00K
Free Cash Flow-15.09M-11.83M-16.82M-18.25M-2.52M-45.06M-55.68M-78.49M-155.68M-148.98M-222.93M-24.71M22.07M-19.25M20.65M-22.83M14.37M38.86M41.73M
Dividends Paid----0000000--------
FCF to OCF100.00%100.00%100.00%100.00%137.96%102.41%101.14%101.67%100.76%105.14%129.24%102.53%98.63%-2405.75%100.00%144.23%53.20%99.86%99.83%
Dividend Paid to FCF----0.00%0.00%0.00%0.00%0.00%0.00%0.00%--------

Earnings

Report DateMay 15, 2012Aug 14, 2012Nov 14, 2012Mar 31, 2013May 9, 2013Aug 6, 2013Nov 12, 2013Mar 3, 2014May 12, 2014Aug 11, 2014Nov 10, 2014Mar 2, 2015May 11, 2015Aug 10, 2015Nov 9, 2015Feb 29, 2016May 10, 2016Aug 9, 2016Nov 9, 2016Mar 1, 2017May 10, 2017Aug 9, 2017Nov 9, 2017Mar 1, 2018May 9, 2018Aug 9, 2018Nov 1, 2018Feb 28, 2019May 9, 2019Aug 8, 2019Nov 6, 2019Feb 20, 2020May 7, 2020Aug 6, 2020Nov 5, 2020Feb 25, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Mar 3, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Mar 2, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Feb 29, 2024May 2, 2024Aug 1, 2024Nov 7, 2024Feb 26, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 26, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-0.24-0.31-0.58-0.75-0.46-0.45-0.41-0.49-0.40-0.62-0.79-1.19-1.06-1.42-1.56-1.95-1.99-2.17-1.96-1.92-1.20-1.31-1.42-1.97-0.31-0.82-0.45-0.77-0.20-0.89-0.45-0.26-0.680.14-0.14-0.310.34-0.14-0.22-0.09-0.110.090.030.01-0.010.070.140.30-0.15-0.100.380.14-0.020.080.090.19-0.130.060.06
EPS Actual-0.56-0.74-1.29-0.83-0.41-0.44-0.43-0.56-0.50-1.05-0.84-1.57-1.02-1.13-1.10-1.90-1.28-1.17-1.11-2.04-1.16-1.38-1.36-1.710.02-0.590.16-0.800.20-0.57-0.120.01-0.200.35-0.60-0.380.550.32-0.990.10-0.010.280.05-0.120.090.100.170.26-0.05-0.050.450.430.060.120.210.26-0.040.16-
Surprise-133.33%-138.71%-122.41%-10.67%10.87%2.22%-4.88%-14.29%-25.00%-69.35%-6.33%-31.93%3.77%20.42%29.49%2.56%35.68%46.08%43.37%-6.25%3.33%-5.34%4.23%13.20%106.45%28.05%135.56%-3.90%200.00%35.96%73.33%103.85%70.59%150.00%-328.57%-22.58%61.76%328.57%-350.00%211.11%90.91%211.11%66.67%-1300.00%1000.00%42.86%21.43%-13.33%66.67%50.00%18.42%207.14%400.00%50.00%133.33%36.84%69.23%166.67%-
TimingAfter-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap506.91M
Enterprise Value390.21M
Trailing P/E19.25
Forward P/E3.46
PEG Ratio0.03
Price / Sales2.19
Price / Book3.46
EPS0.51
Book Value2.71
Revenue (TTM)231.24M
Gross Profit (TTM)173.04M
EBITDA40.12M
Profit Margin11.55%
Operating Margin13.42%
Return on Equity21.97%
Return on Assets9.81%
Shares Outstanding51.62M
Shares Float39.64M
Beta1.23
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 1 analystsTarget 6.00
  • Hold
    1

Ownership Breakdown

Institutions
75.68%
Insiders
15.28%
Retail / Other
9.04%

Top Institutional Holders

  • BlackRock Inc
    3.60M6.97%
  • American Century Companies Inc
    2.32M4.49%
  • Acadian Asset Management LLC
    2.04M3.96%
  • Renaissance Technologies Corp
    1.94M3.76%
  • Vanguard Capital Management, LLC
    1.82M3.52%
  • Vanguard Portfolio Management, LLC
    1.73M3.36%
  • LSV Asset Management
    1.62M3.13%
  • Dimensional Fund Advisors, Inc.
    1.52M2.94%
  • O'Shaughnessy Asset Management LLC
    1.14M2.20%
  • Geode Capital Management, LLC
    1.02M1.97%
  • State Street Corp
    917.59K1.78%
  • Kennedy Capital Management Inc
    873.25K1.69%
  • AQR Capital Management LLC
    800.19K1.55%
  • Connor Clark & Lunn Inv Mgmt Ltd
    782.80K1.52%
  • Bridgeway Capital Management, LLC
    775.34K1.50%
  • Comprehensive Portfolio Management, LLC
    749.80K1.45%

Top Fund Holders

  • Avantis US Small Cap Value ETF
    2.26M4.38%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.34M2.60%
  • iShares Russell 2000 ETF
    1.16M2.25%
  • Vanguard Explorer Inv
    777.39K1.51%